Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does Initial Atopic Dermatitis Severity Affect Long-Term Abrocitinib Outcomes? A Post Hoc Analysis of Two Randomized Trials

  • By

  • Andrew E. Pink

  • Zakiya P. Rice

  • Melinda J. Gooderham

  • Fang Wang

  • Andreas Wollenberg

  • Pinaki Biswas

  • Gary Chan

  • Justine Alderfer

  • Melissa Watkins

  • October 8, 2026

Share

Clinical Report: Does Initial Atopic Dermatitis Severity Affect Long-Term Abrocitinib Outcomes? A Post Hoc Analysis of Two Randomized Trials

Related Resources & Content

  1. Dermatology and Therapy — Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis
  2. Dermatology and Therapy — Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis
  3. Frontiers in Immunology — Real-World Effectiveness and Safety of 200 mg Abrocitinib Initiation in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: A Retrospective Study
  4. Dermatology and Therapy — A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
  5. American Academy of Dermatology issues first-ever pediatric atopic dermatitis guidelines, highlighting prevention strategies and effective treatments
  6. Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years - Gooderham - 2026 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
  7. Upadacitinib Leads in Efficacy: A Bayesian Network Meta-Analysis of Four JAK Inhibitors in Moderate-To-Severe Atopic Dermatitis - PubMed

Original Source(s)

Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials

  • by Andrew E. Pink, Zakiya P. Rice, Melinda J. Gooderham, Fang Wang, Andreas Wollenberg, Pinaki Biswas, Gary Chan, Justine Alderfer, Melissa Watkins

  • October 8, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”

Daily Itch Duration Linked to Quality-of-Life Burden

Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.